RenovaCare Announces Termination of StemCell Systems R&D Agreement
Scottsdale, AZ – May 3, 2022 – RenovaCare, Inc. (Symbol: RCAR; www.renovacareinc.com), clinical-stage developer of patented cell therapy technologies for the regeneration of skin and tissues, today announced the termination of its Strategic R&D Agreement with StemCell Systems and the closure of the RenovaCare R&D Innovation Center in Berlin, Germany.